| Dr Farid Besharat, MD | |
|
1400 S Grand Ave, Ste 815, Los Angeles, CA 90015-3068 | |
| (310) 914-9150 | |
| (310) 914-9705 |
| Full Name | Dr Farid Besharat |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 37 Years |
| Location | 1400 S Grand Ave, Los Angeles, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366548620 | NPI | - | NPPES |
| 00A495041 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | A49504 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Los Angeles Community Hospital | Los angeles, CA | Hospital |
| Memorial Hospital Of Gardena | Gardena, CA | Hospital |
| L A Downtown Medical Center, Llc | Los angeles, CA | Hospital |
| Entity Name | Farid Besharat Md Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134214620 PECOS PAC ID: 0143654335 Enrollment ID: O20191220001950 |
News Archive
Patients with type 2 diabetes that were treated with a weekly injection of the breakthrough drug Semaglutide were able to achieve an average weight loss of nearly 10kg, according to a new study published in The Lancet today.
Researchers from the Centers for Disease Control and Prevention (CDC) have conducted a study showing that face masks and neck gaiters appear to be much more effective than face shields at reducing the expulsion of respiratory aerosols that could potentially transmit severe acute respiratory syndrome 2 (SARS-CoV-2).
VeriChip Corporation ("VeriChip") (NASDAQ: CHIP) and its development partner RECEPTORS LLC, a technology company whose AFFINITY by DESIGN™ chemistry platform can be applied to the development of selective binding products, announced today that VeriChip has been granted an exclusive license to RECEPTORS' Patent No. 7,504,364 titled "Methods of Making Arrays and Artificial Receptors" and Patent No. 7,469,076 "Sensors Employing Combinatorial Artificial Receptors," in their application to the development of the virus triage detection system for the H1N1 virus.
A new study published in the March issue of The American Journal of Pathology suggests that cortical type 2 cannabinoid (CB2) receptors might serve as potential therapeutic targets for cerebral ischemia.
Researchers in the University of São Paulo's School of Physical Education and Sports (EEFE-USP) in Brazil compared the effect of two widely used classes of anti-hypertensive drugs on post-exercise hypotension, an expected and beneficial fall in blood pressure after a session of aerobic exercise, especially in the late afternoon or early evening.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Farid Besharat, MD 1400 S Grand Ave, Ste 815, Los Angeles, CA 90015-3068 Ph: (310) 914-9150 | Dr Farid Besharat, MD 1400 S Grand Ave, Ste 815, Los Angeles, CA 90015-3068 Ph: (310) 914-9150 |
News Archive
Patients with type 2 diabetes that were treated with a weekly injection of the breakthrough drug Semaglutide were able to achieve an average weight loss of nearly 10kg, according to a new study published in The Lancet today.
Researchers from the Centers for Disease Control and Prevention (CDC) have conducted a study showing that face masks and neck gaiters appear to be much more effective than face shields at reducing the expulsion of respiratory aerosols that could potentially transmit severe acute respiratory syndrome 2 (SARS-CoV-2).
VeriChip Corporation ("VeriChip") (NASDAQ: CHIP) and its development partner RECEPTORS LLC, a technology company whose AFFINITY by DESIGN™ chemistry platform can be applied to the development of selective binding products, announced today that VeriChip has been granted an exclusive license to RECEPTORS' Patent No. 7,504,364 titled "Methods of Making Arrays and Artificial Receptors" and Patent No. 7,469,076 "Sensors Employing Combinatorial Artificial Receptors," in their application to the development of the virus triage detection system for the H1N1 virus.
A new study published in the March issue of The American Journal of Pathology suggests that cortical type 2 cannabinoid (CB2) receptors might serve as potential therapeutic targets for cerebral ischemia.
Researchers in the University of São Paulo's School of Physical Education and Sports (EEFE-USP) in Brazil compared the effect of two widely used classes of anti-hypertensive drugs on post-exercise hypotension, an expected and beneficial fall in blood pressure after a session of aerobic exercise, especially in the late afternoon or early evening.
› Verified 4 days ago
Dr. Linda Fong, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 6041 Cadillac Ave, Los Angeles, CA 90034 Phone: 323-857-3290 | |
Dr. Robert Peter Gale, Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 11693 San Vicente Blvd, Suite 335, Los Angeles, CA 90049 Phone: 310-442-9010 | |
Dr. Tarek Alasil, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 8616 La Tijera Blvd Ste 404, Los Angeles, CA 90045 Phone: 310-673-2020 Fax: 310-469-5290 | |
David Michael Tellalian, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 8635 W 3rd St Ste 465w, Los Angeles, CA 90048 Phone: 310-358-2300 Fax: 310-358-2308 | |
Dr. Jan B King, M.D., M.P.H. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 11833 Wilmington Ave Fl 2, Los Angeles, CA 90059 Phone: 323-568-8701 | |
Dr. Caroline Hwang, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1520 San Pablo St, Suite 1000, Los Angeles, CA 90033 Phone: 323-442-5100 | |
Dr. Jennifer A Fulcher, M.D., PH.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 10833 Le Conte Ave, Chs 37-121, Los Angeles, CA 90095 Phone: 310-825-7225 |